期刊名称：PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Progress in Neuro-Psychopharmacology
& Biological Psychiatry
Progress in Neuro-Psychopharmacology & Biological Psychiatry is an international and multidisciplinary research, review and news journal. One of its main aims is to assure rapid publication of authoritative reviews and research papers dealing with experimental and clinical aspects of neuro-psychopharmacology and biological psychiatry. Another important aim of the journal is to supply pertinent information, provided by national and international bodies, that contributes to progress in the scientific and professional fields. Finally, the journal intends to foster and encourage communications between members of the communities of neuro-psychopharmacology and biological psychiatry.
Abstracting / Indexing
- BIOSIS
- Cambridge Scientific Abstracts
- Chemical Abstracts
- Current Contents/ISI/BIOMED Database
- Current Contents/Index to Scientific Reviews
- Current Contents/Life Sciences
|
- EMBASE
- Elsevier BIOBASE
- Index Medicus
- Research Alert
- SCISEARCH
- Science Citation Index
|
Instructions to Authors
Submission of Manuscripts
Title page, abstract (including key words and abbreviation list), tables, legends to figures and reference list should each be provided on separate sheets of paper.
Language
Articles should be submitted in English. If English is not their native language, authors are recommended to consult a colleague whose English could be regarded as impeccable.
Number of copies
Four double spaced copies on 8?x 11 in. paper should be sent to the address below two sets of original glossy prints (essential for photographs) should be provided. Photocopies or good reproductions of illustrations are acceptable only on the spare copies.
It is understood that neither the manuscript nor the data it contains have been previously published nor are being submitted elsewhere for publication.
Organization of manuscripts
Each type of article should contain the following parts:
1. Original articles (full length and short papers): 1) title page; 2) abstract; 3) keywords; 4) abbreviations; 5) introduction; 6) methods; 7) results; 8) discussion; 9) conclusion; 10) acknowledgments; 11) references; 12) tables; 13) figures; 14) legends for figures.
2. Review articles (mini-reviews or comprehensive reviews); 1) title page; 2) abstract; 3) keywords; 4) abbreviations; 5) introduction.
After the introduction, each review article should have its own framework. Contributors should prepare a well-structured text using appropriate headings and subheadings. It is also highly recommended that review articles be well illustrated so that interested but non-expert readers can easily and rapidly understand the text. For further information, invited author or authors who want to submit a review article should contact the Editorial Office at the address given below.
Specific recommendations for original articles
1. Title page. This should contain:
|
1.1. Complete title of the article without abbreviations.
1.2. Names of all authors, with an asterisk beside the name of the corresponding author.
1.3. Full mailing addresses of each author, including the name of the institution and the department.
1.4. Links (lowercase roman letters) connecting authors with their affiliations (all of the authors' names should be on one line and all of their affiliations on another; if authors share an affiliation, they should share the link). |
2. Abstract page. This should contain:
|
2.1. Abstract representing in concise form the purpose, the general methods, the findings and the conclusions of the authors.
2.2. Keywords in alphabetical order, given as an aid to indexing.
2.3. Abbreviations. Whenever an abbreviation other than those listed under General recommendations is used in an article, it is to be defined in text at first mention. An alphabetical list of abbreviations, followed by their full terms, should be placed under the keywords. |
3. Body of the text
|
3.1. Introduction. This section should contain a clear statement of the general and specific objectives as well as the hypotheses which the work is designed to test. It should also give a brief account of the reported literature. The last sentence should clearly state the purpose of the article.
3.2. Methods. This section should contain explicit, concise descriptions of all procedures, materials and methods used in the investigation to enable the reader to judge their accuracy, reproducibility, etc. To increase clarity, headings should be used throughout. For example, the following subheadings, which should be numbered, could be used: |
|
|
3.2.1. Experimental articles (full length or short papers): Animals, Drugs, Apparatus, Experimental procedure, and Statistical analysis.
3.2.2. Clinical articles (full length or short papers): Patient population, Drug administration, Study design, Assessment instruments, and Data analysis. Depending on the type of article they are preparing, authors could introduce any other subheadings they find useful. |
|
3.3. Results. This section usually contains the experimental data, but no extended discussion of their significance. The results should be illustrated (figures and tables); data are usually easier for readers to grasp if they are represented in graphic or tabular form, rather than discursively. Graphic presentation of data is preferred. Data should not be needlessly repeated in text. Sufficient data may allow interested but non-expert readers to judge the variability and reliability of the results. The section should be well structured using appropriate subheadings.
3.4. Discussion. This should be pertinent to the results. Speculative discussion is not discouraged provided it is based on the data presented. The discussion should be as concise as possible and well structured, using appropriate subheadings.
3.5. Conclusions. A short paragraph of conclusions (5 to 10 lines) should be included. |
4. Acknowledgments. These may be included at the end of the text before the References; they should have a separate heading.
5. References
|
5.1. In text, citations should quote the authors' name(s) and the year of publication (e.g. Fukuda 2000; Bird and Parlee, 2000). With more than two authors, text citations should contain the name of first author, followed by "et al.," and the date (e.g. Post et al., 2000).
5.2. In the reference list, entries are to be arranged alphabetically by author, and not numbered. All authors' names are to be given. If reference is made to more than one publication by the same authors in the same year, suffixes (a, b, c etc.) should be added to the year both in the text citation and in the list references. Below are examples of 5 references. |
|
|
5.2.1. Journal article
Kannel, W.B., Belanger, A.J., 1991. Epidemiology of heart failure, Am. Heart J. 121, 951-957.
5.2.2. Journal supplement
Costard-Jackle, A., Fowler, M.B., 1992, Pulmonary artery pressure: Testing of hypertension, J. Am. Coll. Cardiol. 19 (Suppl. 290), S48-S54.
5.2.3. Article or chapter in edited book
Gross, S.S., Aisaka, K., Jaffe, E.A., 1990. Nitric oxide synthesis. In: Levi, R., Griffith, O.W. (Eds.), Biochemistry Basics, Biopub Inc., New York, pp. 96-103.
5.2.4. Proceedings published as a book
Addonizio, L.J., Robbins, R.C., 1987, Pulmonary vascular resistance. In: Smith, J.K. (Ed.), Proceedings of the Fourth International Symposium on Circulation. Real Science Press, Las Vegas, NV, pp. 12-189.
5.2.5. Book
Palmer, Jr., R.J., Moncada, S., 1988. Vascular Endothelial Cells, third ed. Science Publishers, New York (Chapter 11). | See BioSciences Information Services of Biological Abstracts for standard abbreviations for journals. Citations of personal communications or of unpublished observations should be given in parentheses at the appropriate place in the text, not in the list of references. An article may not be cited "in press" unless it has been accepted for publication. In such cases, the name of the journal should be given.
6. Tables. All tables must be cited in the text, have brief, descriptive titles and be consecutively numbered with Arabic numerals. Information other than that defining the data should be presented as footnotes. Use lowercase roman letters for footnotes. Only horizontal rules should be included, and kept to a minimum.
7. Illustrations. Each illustration should be clearly marked on the reverse side with the name of the corresponding author, the number of the illustration and its orientation (top); use a soft pencil or felt-ripped pen, and do not press hard against the surface.
|
7.1. Photographs. Photographs should be glossy prints with high contrast. Magnification should be indicated by a line representing the actual scale of reproduction (0.1  m, 1 m). Avoid the use of magnification factors whenever possible.
7.2. Line figures. Figures will not be redrawn by the Publisher. They should be black ink on white paper, or black and white prints. Do not place the title of the figure within the figure itself. The size of the lettering should be consistent, taking into consideration the possibility of reduction.
7.3. Color figures. The authors will be charged the cost of reproducing figures in color. |
8. Legends for figures. These should be typed on a separate page, double spaced as part of the text. Legends, should be numbered consecutively in Arabic numerals. Legends should explain the figures in sufficient detail so that repeated referral to the text is unnecessary. Abbreviations in the legends should conform to those in the text.
9. Footnotes. These are best avoided or they should be kept to a minimum. When used, they should be typed at the bottom of the appropriate page and separated from the text by a short line. Footnotes should be used for authors' degrees and positions, proprietary names and trademarked drugs and other materials not appropriately referred to in the text or in the reference list.
General recommendations
Abbreviations
The following abbreviations or their properly prefixed multiples and submultiples may be used without definition in the text, tables or figures (Notice to contributors, 1981, J. Pharmacol. Exp. Ther.):
Drug nomenclature
Generic names should be used in text, tables and figures. Trade names and the name and city of their manufacturer may be mentioned in parentheses in the first text reference to the drug, but should not appear in titles, figures or tables. Chemical names could also be used. Code numbers could be given in brackets. When a trade name is used, it should be capitalized; general or chemical names are not capitalized. The chemical nature of new drugs must be given when known. The form of drug used in calculations of doses (e.g., base or salt) should be indicated.
Ethics of experimentation
Procedures involving experiments on human subjects should be in accordance with the ethical standards of the Committee on Human Experimentation of the institution in which the experiments were done or in accordance with the Helsinki Declaration of 1975. Procedures involving experimentation on animals should be done in accordance with the guidelines of the institution in which the experiments were done or local government regulating bodies.
Reprints
The Publisher will supply to the main author 25 reprints free of charge. Further reprints can be supplied at a reasonable price. Authors should complete the reprint request form supplied by the Publisher and return it with the signed copyright transfer form, also supplied by the Publisher.
Mailing
Place disks in a disk mailer; place manuscripts between thick cardboard when mailing.
Proofs
If the e-mail address of the corresponding author is provided, the author will receive his proofs as a PDF attachment to an e-mail. To view these proofs, the author must have Acrobat Reader, which is available free of charge from Adobe (download from http://www.adobe.com/products/acrobat/readstep.html). If no e-mail address is provided, or if the corresponding author prefers page proofs, those will be sent instead.
Elsevier will do everything possible to get your article corrected and published as quickly and accurately as possible, both online (ScienceDirect) and in print. Therefore, it is important to ensure that all your corrections are sent back to us in one communication. Subsequent corrections will not be possible, so please ensure your first sending is complete.
Further information
For any information regarding the preparation and forwarding of manuscripts, authors may contact:
Editorial Office:
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
Unit?de recherche en neuroscience
RC9800, Centre de Recherche du CHUL
2705 boul, Laurier
Sainte-Foy, (Québec)
CANADA G1V 4G2
Tel: (418) 656-4141 (ext: 8531); Fax: (418) 654-2753
Email: monique.baron@crchul.ulaval.ca
Editorial Board
Editor-in-Chief:
P. Bédard, Unit?de Recherche en Neuroscience, RC9800, Centre de Recherche du CHUL, Centre Hospitalier de L'Universit?Laval, 2705 Boulevarde Laurier, Sainte-Foy, Quebec, G1V 4G2, Canada
Honorary Editor-in-chief:
C. Radouco-Thomas, Laval University Medical School, Quebec, Canada
Mailing Address:
Editorial Office, Progress in Neuro-Psychopharmacology & Biological Psychiatry, Unit?de Recherche en Neuroscience Research Section, Centre de Recherche du CHUL, Local RC-9800, 2705 Blvd, Laurier, St?Foy, Quebec, Canada, G1V 4G2
Editorial Board:
G Agam, Beer-Cheva, Israel
J.D. Amsterdam, Philadelphia, PA, USA
R.J. Baldessarini, Belmont, MA, USA
T.A. Ban, Toronto, Canada
N. Barden, St?Foy, Canada
G.D. Burrows, Melbourne, Australia
N.R. Cutler, Los Angeles, CA, USA
C. De Montigny, Montreal, Canada
E.F. Domino, Ann Arbor, MI, USA
V.A. Glover, London, UK
F.K. Goodwin, Bethesda, MD, USA
T. Hokfelt, Stockholm, Sweden
F.H. Holsboer, Munich, Germany
L.L. Judd, San Diego, CA, USA
K. Kalant, Toronto, Canada
M.H. Lader, London, UK
Y. Lecrubier, Paris, France
K. Maeda, Kobe, Japan
M. Maes, Maastricht, The Netherlands
K. Maziade, Quebec, Canada
N.K. Mello, Belmont, MA, USA
H.Y. Meltzer, Chicago, IL, USA
J. Mendlewicz, University of Brussels, Brussels, Belgium
D. Moussaoui, Casablanca, Morroco
C.B. Nemeroff, Atlanta, GA, USA
G. Pepeu, Florence, Italy
P. Pichot, Paris, France
D. Pickar, Bethesda, MD, USA
R.M. Post, NIMH, Bethesda, MD, USA
G. Racagni, Institute of Pharmacology, Milan, Italy
O. Ray, Nashville, TN, USA
T. Svensson, Stockholm, Sweden
D.P. Van Kammen, Pittsburgh, PA, USA
H.M. Van Praag, University of Limburg, Maastricht, The Netherlands
A. Wirz-Justice, Basel, Switzerland
|
